LLY Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Eli Lilly and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.27 |
| 52 Week High | US$30.16 |
| 52 Week Low | US$21.17 |
| Beta | 0.37 |
| 1 Month Change | 2.16% |
| 3 Month Change | 17.41% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 31.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| LLY | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 6.3% | 8.8% | -0.5% |
| 1Y | n/a | 64.2% | 5.3% |
Return vs Industry: Insufficient data to determine how LLY performed against the Canadian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how LLY performed against the Canadian Market.
Price Volatility
| LLY volatility | |
|---|---|
| LLY Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 15.2% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: LLY has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LLY's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
| LLY fundamental statistics | |
|---|---|
| Market cap | CA$967.66b |
| Earnings (TTM) | CA$8.45b |
| Revenue (TTM) | CA$49.44b |
113.9x
P/E Ratio19.5x
P/S RatioIs LLY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LLY income statement (TTM) | |
|---|---|
| Revenue | US$35.93b |
| Cost of Revenue | US$7.13b |
| Gross Profit | US$28.80b |
| Other Expenses | US$22.66b |
| Earnings | US$6.14b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
| Earnings per share (EPS) | 6.82 |
| Gross Margin | 80.16% |
| Net Profit Margin | 17.08% |
| Debt/Equity Ratio | 204.3% |
How did LLY perform over the long term?
See historical performance and comparison